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Abstract 
 
OBJECTIVES: Notwithstanding the growing proportion of HIV-1 non-B 
subtypes in Europe, the impact of their genetic background on 
response to antiretroviral therapy is still unclear. The aim of this study 
was to compare response to protease inhibitor (PI) or non-nucleoside 
reverse transcriptase inhibitor (NNRTI) containing regimens in patients 
carrying non-B or B clades with matched resistance mutation patterns. 
 
METHODS: We analyzed HIV-1 pol sequences of 1,108 patients stored 
in the ARCA (Antiretroviral Resistance Cohort Analysis) database and 
obtained before treatment. Response to therapy was defined as viral 
load suppression below 50 HIV-1 RNA copies/ml at week 12. By 
evaluating the combination of major resistance mutations, genotype 
coding generated 35 and 12 different vectors for PI or NNRTI 
treatments.  
 
RESULTS: The proportion of subjects achieving virological suppression 
was comparable in patients with non-B or  B variants stratified for 
treatment status (51.5% vs. 41.5% in naïve and 46.7% vs. 38.7% in 
experienced patients) and regimens including PIs (46.9% vs. 39.7%) 
or NNRTIs (56.7% vs. 40%). No difference in response to therapy in 
patients with non-B and B HIV-1 was observed in any matched 
genotype with respect to treatment combination. When B vs. specific 
non-B clades (C, F1, CRF02_AG) were compared, the only difference 
was a better response of CRF02_AG compared to B clade (75.0% vs. 
36.7%; p=.012).  
 
CONCLUSIONS: Response to PI- and NNRTI-based therapy is 
comparable in patients carrying non-B or B subtype matched for HIV-1 
pol genotype. Further clade-specific studies are advisable to 
investigate possible minor effects on response to treatment. 
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The origin and variability of HIV  
 
 
HIV-1 pandemic is a relevant challenge for global health nowadays, 
with more than 35 million people living with this infection [1]. The 
virus was originated in West and Central Africa from a zoonotic 
transmission of simian immunodeficiency virus (SIV) from non-human 
primates. HIV type 1 (HIV-1) groups M, N, O and P and HIV type 2 
(HIV-2) groups A-H were generated by independent zoonotic 
transmission events. HIV-1 group M, the pandemic branch of HIV, 
originated from SIVcpz in the chimpanzee Pan troglodytes troglodytes 
[2].  
After transmission to humans at the beginning of the century, HIV-1 
group M probably diversified into genetic subtypes (named A-D, F-H 
and J-K) during the first decades of the 20th century [3]. 
Recombinants between subtypes have been designated as circulating 
recombinant forms (CRFs) if fully sequenced and found in three or 
more epidemiologically unlinked individuals. At present, 54 different 
CRFs have been described. Recombinants are defined unique 
recombinant forms (URFs) if not meeting these criteria [4].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Phylogenetic tree 
showing relationships between 
SIV, HIV-2 and HIV-1. 
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subtypes and CRFs co
 
 
 
 
Figure 2. Distribution of 
different geographical areas 
5). 
Introduction
, such as CRF01_AE and CRF02_AG, were formed 
played important roles in regional 
ther CRFs were generated
 where different 
-circulate continuously giving rise to URFs. 
main HIV-1 subtypes and recombinants 
worldwide. (Figure reproduced from Ref
 
7
new 
to 
 elsewhere in 
 
 
in 
. 
Introduction 
 8
 
In the second half of the 20th century the global spread of HIV-1 
group M resulted in a differential global distribution of HIV-1 subtypes 
and recombinants, as shown in Figure 1.  
Notably, the circulation of non-B clades has recently increased in 
previously subtype B-restricted areas such as Western Europe and 
North America, mainly due to immigration from other regions of the 
world [5].  
The analysis of HIV-1 heterogeneity has shown a high inter-subtype 
nucleotide sequence divergence in gag, pol and env genes [6]. This 
genetic variability of HIV results from recombination and the high 
mutation rates of the reverse transcriptase enzyme, which lacks a 
proof-reading mechanism, and to the high rates of viral replication. 
Also within a single individual viral sequences can differ by up to 10% 
[7] and genetic variation within a subtype is generally in the order of 
8-17%, sometimes reaching more important proportions, as high as 
30%. Variation between subtypes is usually between 17 and 35% but 
can be up to 42% [7].  
The high variability may lead to specific differences among different 
subtypes in pathogenesis, infectivity, resistance to antiretrovirals and 
response to therapy. 
 
 
The impact of HIV variability 
 
The origin and molecular epidemiology of HIV, as far as their potential 
impact on disease progression, have recently been comprehensively 
reviewed [8, 9]. HIV-1 variability is crucial in describing the size and 
features of the pandemic, since groups, subtypes and recombinants 
differ in both epidemic size and geographical spread (Figure 1). It is 
uncertain whether the differential strain distribution can be accounted 
Introduction 
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for by founder effects alone or if intrinsic biological properties of the 
different HIV variants have played a role in their differential spread. 
Nevertheless, it is somehow described an impact of HIV diversity on 
cell biology, transmission, pathogenesis and clinical management. In 
addition, a key role of escape mutations in the immune response to 
HIV has been described and challenges to HIV vaccine development 
have risen from HIV diversity [10]. 
 
 
 
 
 
 
 
 
 
Figure 3. The role of HIV diversity: aspects of HIV infection 
which are affected by the viral genetic variability (Figure 
reproduced from Ref. 9). 
 
 
A recent study found that human genetic variation, together with 
demographic variables, accounted for only 22% of the variability in 
HIV viral load and disease progression rates. Other factors, including 
environmental and viral factors, seem to be responsible for the 
remaining 78% of divergence in the clinical progression of the disease 
[11]. 
While these effects have been shown within subtype B infected 
populations, subtypes may play a significant role in determining viral 
load setpoint, considering the large genetic variability between 
subtypes. Indeed, cohort studies performed in areas where different 
subtypes co-circulate have provided some insights. According to recent 
studies, subtype C appeared to have a higher viral load and lower CD4 
Introduction 
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counts than those infected with subtype A [12], while CRF02_AG 
seems to have a higher viral load than other subtypes [13]. 
Some independent African studies indicated that subtype D infection is 
associated with faster disease progression to death than subtype A in 
populations where these subtypes co-circulate [14, 15]. This reduced 
survival was found in association with lower CD4 counts in subtype D 
infection rather than subtype A [14. 15]. Moreover, among individuals 
with advanced immunosuppression, subtype D was also associated 
with higher rates of dementia compared to subtype A [16]. 
As a possible consequence of different pathological properties, studies 
from Uganda and Kenya found significant decreases in the prevalence 
of subtype D and increases in subtype A frequency overtime [17, 18]. 
The changes in these proportions may have an explanation in both the 
faster disease progression and lower rate of heterosexual transmission 
of subtype D. 
 
 
HIV variability and response to therapy 
 
Previous studies did not show significant variations in virologic and 
immunologic responses to highly active antiretroviral therapy (HAART) 
between HIV-1 subtype B and all non-B subtypes grouped together. No 
differences in achieving viral load suppression following treatment did 
emerge in limited comparisons between subtype B and specific non-B 
variants such as clades C, A, D and CRF02_AG [19-23]. 
Moreover, information regarding resistance to antiretroviral drugs has 
been mainly derived from patients infected with HIV-1 subtype B [24].  
The selection of resistance to antiretroviral drugs continues to be an 
important problem in the treatment of HIV-infected individuals. 
Indeed, most major resistance mutations in subtype B are also found 
Introduction 
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in non-B subtypes, but several novel mutations occur in non-B 
subtypes [25]. 
Although most of the resistance-associated mutations have been 
characterized in subtype B viruses, they are also found in treatment-
failing patients harboring non-B subtypes [26, 27].  
Nevertheless, some differences have been documented in the 
pathways to resistance in different clades [28] and subtype-specific 
natural polymorphisms have been suggested to play a possible role in 
drug activity in vitro and in vivo in some studies [29]. 
Of note, of 67 resistance mutations found in non-B subtype, 61 were 
also seen in subtype B isolates, indicating that some novel mutations 
only occur in non-B subtypes [25]. Examples of the latter are the non-
nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutation 
V106M which occurs in subtype C and CRF01_AE and the protease 
inhibitor (PI) mutation L891V which has been described in subtypes C, 
F and G [30]. The mutational pathway leading to resistance is shorter 
in some non-B subtypes, which may have a role in the faster 
development of cross-resistance and compromise second-line regimens 
[30]. A differential pathway leading to resistance to is well known for 
mutation K65R, which has a faster selection in subtype C rather than 
in B clade [31] and has an important role in conferring resistance to 
non-nucleos(t)ide reverse transcriptase inhibitors (NNRTI). 
Among specific non-B subtypes some differences are also notable. In 
fact, nevirapine resistance mutations seem to develop more frequently 
in subtype D than A in a mother-to-child transmission prevention study 
using single-dose nevirapine [32].  
Of note, among strains not belonging to group M a high proportion of 
group O viruses are naturally resistant to NNRTIs due to the presence 
of the C181Y substitution in the RT region [33]. 
 
 
Introduction 
 12
Aim of this study 
 
Since the majority of data about highly active antiretroviral therapy 
(HAART) efficacy and resistance has been obtained from clinical trials 
involving mainly patients harboring subtype B virus, implications of 
subtype divergence in HAART efficacy still need to be studied in detail. 
This achievement is urgent because antiretroviral drugs are being 
introduced into developing countries where non-B subtypes are highly 
prevalent and non-B clades are expanding in previously clade B 
homogeneous areas, including Italy [34-39]. 
The aim of this study was to explore an innovative methodology to 
compare the impact of specific patterns of mutations on virological 
response to treatment in patients harboring different HIV-1 clades. 
Herein, we evaluated the overall and subtype specific response to PI or 
NNRTI containing regimens in patients carrying non-B or B clades with 
matched pre-therapy genotype, in a multicenter nationwide cohort. 
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Inclusion criteria and endpoints 
 
Patients included in this analysis participated to the Antiretroviral 
Resistance Cohort Analysis (ARCA, www.hivarca.net) database and gave 
their informed consent to have their anonymised data stored on a central 
server and used for non-profit research purposes.  
Patient cases were selected based on availability of baseline HIV-1 
genotype obtained at maximum 12 weeks before treatment start and 
availability of a 12-week (range 8-16 weeks) follow-up HIV-1 RNA 
determination. Response to therapy was defined as viral load suppression 
below 50 HIV-1 RNA copies/ml at week 12. As secondary end-points HIV-
1 viral load reduction between baseline and 12-week follow up and 
proportions of individuals reaching undetectable viral load at week 24 
were also considered. Comparisons between response to treatment in 
subjects carrying B and non-B variants were conducted with and without 
matching for baseline resistance pattern and treatment (see below). 
 
 
Genotypic resistance and subtype assignment  
 
Resistance mutations were identified for IAS-USA 2011 tables [40]. 
Subtyping was based on a partial HIV-1 pol sequence about 1,000 to 
1,280 nucleotides long, depending on the sequencing protocol used at 
the contributing laboratory. Sequences were firstly analyzed using the 
NCBI HIV-1 subtyping tool to discriminate between B and non-B strains.  
Non-B sequences were subsequently aligned to the most recent reference 
dataset from Los Alamos National Laboratory website 
(http://hiv.lanl.gov/) using BioEdit 7.0.5 and ClustalX 1.83. The resulting 
alignment was analyzed with Phylip package version 3.67 
(http://evolution.genetics.washington.edu/phylip.html) building a 
Neighbor-Joining tree based on the F84 substitution model. Reliability of 
the tree topology was assessed through bootstrapping using 1,000 
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replicate datasets. Sequences that could not be unequivocally assigned to 
a pure subtype or CRF were considered as possible recombinants and 
examined using Simplot 3.5.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mutations in the reverse transcriptase gene associated with 
resistance to reverse transcriptase inhibitors [40]. 
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Figure 5. Mutations in the protease gene associated with resistance to 
protease inhibitors [40]. 
 
HIV-1 genotype and treatment coding 
 
Response to therapy was evaluated in patients carrying either non-B or B 
subtypes with matched resistance patterns and treatment type. HIV-1 
genotype was coded by considering the following mutations: any 
thymidine analogue mutations (TAMs) (M41L, D67N, K70R, L210W, 
T215Y/F and K219Q/E), K65R, L74I/V, Q151M, 69ins, M184I/V, any 
major NNRTI mutation (K103N/S/T, Y181C/I, Y188C/H/L, G190A/E/S/T) 
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and the number (0, 1-3, or >3) of major PI mutations (D30N, I47A/V, 
G48V, I50L/V, I54L/M, L76V, V82A/F/L/S/T, N88D/S, I84V, L90M). 
Treatments were coded as two nucleoside reverse transcriptase inhibitors 
(NRTIs) plus one NNRTI or two NRTIs plus one PI. Each case was then 
defined by the vector combining resistance pattern and treatment type 
(Table 1).  
 
 
Table 1. Generation of vectors and response evaluation. 
Treatments were coded as 2 NRTIs + NNRTI or 2 NRTIs + PI; each case 
was defined by the vectors combining resistance pattern and treatment. 
Sufficient numerous vectors allowing for statistical analysis were coded 
from 1 to 17. 
 
 
 
 
Statistical analysis 
 
The distribution of study subjects with regard to categorical parameters 
was compared using X2 or Fisher exact test. Standard non parametric 
methods (Wilcoxon signed-rank test) were used to compare the median 
Vectors  Mutation pattern  
TAM  65R  74V  151M  184V  PI a  
1  0  0  0  0  0  0  
2  0  0  0  0  1  0  
3  1  0  0  0  0  0  
4  1  0  0  0  1  0  
5 
…  
1 
…  
0 
…  
0 
…  
0 
…  
0 
…  
1 
…  
 TAM  65R  74V  151M  184V  NNRTI  
14  0  0  0  0  0  0  
15  0  0  0  0  0  1  
16  0  0  0  0  1  0  
17  1  0  0  0  1  0  
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age, HIV-1 RNA levels and CD4 counts.  
The crude and Mantel-Haenszel adjusted odds ratios (OR) of response to 
therapy with 95% confidence interval (CI) were calculated. Univariate 
analysis was performed using logistic regression and a subsequent 
multivariate analysis was done on all variables, using the same tests with 
a full model.  
The changes in HIV-1 viral load following therapy in genotype and 
treatment matched cases derived from HIV-1 B and non-B cases were 
compared by Wilcoxon signed rank test.  
In all tests, a p-value below 0.05 was considered significant. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Results 
  
Characteristics of the population
 
The selection procedure generated 1,108 cases from as many HIV
positive individuals, who had referred to 65 clinical Centres of 13 
Italian regions in the 1997
One hundred twent
mostly represented by CRF02_AG (n=26
The distribution of non
in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Distribution of non
the study population.
*Other: non-B clades 
(n=4), CRF15_01B (n=3),  CRF10_CD (n=2), CRF09_cpx (n=2), CRF13_cpx 
(n=1), CRF20_BG (n=1), CRF28_BF (n=1), CRF31_BC (n=1).
 
 
In the overall population different proportions of subjects carrying non
B rather than B strains were observed for ethnicity (Europeans 
accounting for 56.3% and 79.9%, respectively, p<.0001) risk factor 
 
-2009 period.  
y-six individuals (11.4%) harbored non
), F1 (n=25) C (n=20)
-B subtypes and CRFs in our population is shown 
-B subtypes detected in 126 patients of 
 
were CRF01_AE (n=5), CRF12_BF (n=4), CRF06_cpx 
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(heterosexual mode of infection in 81.8% and 43.7% of patients, 
respectively, p<.0001), gender (males in 52% and 68.5% of cases 
p<.0001) and median age (35 vs. 41 years, p=0.01). No difference in 
baseline HIV-1 RNA levels was observed (4.6 vs. 4.6 Log copies/ml), 
while a difference in CD4 cell count at baseline was found in patients 
carrying non-B rather than B variants (201 cells/µl vs. 245 cells/µl, 
p=.0007).  
The prevalence of non-B subtypes was higher among drug-naïve than 
drug experienced patients (20.7%, 66/319 vs. 60/789, respectively, 
p<.0001). The demographic, immunologic and virological data of the 
patients stratified between naïve and experienced individuals are 
shown in Table 1, part A.  
In the overall population, the prevalence of any drug resistance was 
57% (631/1,108). NRTI, NNRTI and PI-associated resistance 
mutations were detected in 52.0%, 28.7% and 24.3%, respectively. 
The prevalence of drug resistance mutations was lower in subjects 
carrying non-B rather than B subtypes, either considering any 
mutation (35.7% vs. 59.7%, p<.0001) or NRTI (33.3% vs. 54.4%, 
p<.0001), NNRTI (12.2% vs. 30%, p=.006) and PI (15.1% vs. 25.5%, 
p=.010) mutations.  
No difference in the proportions of drug resistance was observed 
between non-B and B strains  when grouped in naïve or previously 
experienced individuals. 
Table 1 shows the characteristics of our study population according to 
demographic and immunovirologic parameters, for the whole 
population and for subjects carrying B or non-B variants. 
The distribution of epidemiologic and immunovirologic parameters 
among 319 naïve individuals and 789 experienced individuals is shown 
in Table 3 and 4, respectively. 
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Table 2. Demographic, virological and immunological features of 
1,108 patients enrolled in our cohort. 
 
 
Table 3. Demographic, virological and immunological features among 
319 naïve individuals, according to subtype. 
 
ALL PATIENTS B SUBTYPE NON-B CLADE 
Ethnic group, % (n) 
Europeans 
Africans 
Latin Americans 
Asians 
Others 
 
77.3 (856) 
3.0 (33) 
2.4 (27) 
0.5 (6) 
16.8 (186) 
 
79.9 (785) 
0.3 (3) 
2.5 (24) 
0.5 (5) 
11.4 (126) 
 
56.3 (71) 
23.8 (30) 
2.4 (3) 
0.8 (1) 
0.2 (21) 
Risk factor, % (n) 
Heterosexual sex 
Men having sex with men 
Intravenous drug use 
Other 
 
48 (532) 
20.4 (226) 
28 (310) 
3.6 (40) 
 
43.7 (429) 
21.9 (215) 
31.0 (304) 
3.5 (34) 
 
81.8 (103) 
8.7 (11) 
4.8 (6) 
4.7 (6) 
Gender, % (n) 
Males 
 
68.8 (758) 
 
68.5 (754) 
 
52.2 (71) 
Age (yr), median (IQR*) 40 (36-45) 41 (36-46) 35 (32-43) 
HIV-1 RNA (Log cp/mL), median (IQR) 4.6 (3.9-5.2) 4.6 (3.9-5.2) 4.6 (4.0-5.3) 
CD4 count (cells/mL), median (IQR) 237 (118-380) 245 (128-390) 201 (81-290) 
Total patients, % (n) 100 (1,108) 88.6 (982) 11.4 (126) 
   B subtype Non-B subtype p 
   Ethnic group, % (n)     
       Europeans  
       Africans 
       Latin Americans 
       Asians 
       Others  
 
79.4 (579) 
0.1 (1) 
1.9 (14) 
0.3 (2) 
18.2 (123) 
 
65.7 (34) 
26.7(16) 
3.3 (2) 
0 
13.3 (8) 
 
 
<.0001  
   Risk factor, % (n)  
       Heterosexual sex 
       Men having sex with men 
       Intravenous drug use 
       Other  
 
38.4 (280) 
19.3 (141) 
38.5 (281) 
3.7 (27) 
85.0 (51) 
5.0 (3) 
3.3 (2) 
6.7 (4) 
 
 
<.0001  
   Gender, % (n) 
       Males  
 
69.74 (507) 
 
45.0 (27) 
 
<.0001 
   Age (yr), median (IQR*)  41 (37-45) 36.5 (32-46) .001 
   HIV-1 RNA (Log cp/mL), median (IQR)  4.3 (3.7-5) 4.3 (3.9-4.7) n.s. 
   CD4 count (cells/mL), median (IQR)  262 (150-411) 209 (101-317) .029 
   Total patients, % (n)   92.4 (729) 7.6 (60)  
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Table 4. Demographic, virological and immunological features among 
789 previously experienced patients, according to subtype. 
 
 
 
Previous treatments and starting regimens 
 
Drug experienced patients had a median number of 6 regimens (IQR 
3-9), with a lower number of drug regimens taken in subtype non-B 
vs. B infected individuals (3 vs. 5 median previous regimens, 
p=.0008). The proportion of experienced subjects carrying a non-B 
clade was lower (47.6%) than that found in patients with B strains 
(74.2%) (p<.0001).  
Complete previous treatment history was available for 424 patients. All 
these subjects were NRTI experienced, 53 and 109 patients had 
previously been administered an NNRTI- or PI-containing therapy, 
respectively; 232 received both NNRTIs and PIs.  
Overall, subjects beginning a PI-based HAART regimen were 883. 
   B subtype 
Non-B 
subtype 
p 
   Ethnic group, % (n)     
       Europeans  
       Africans 
       Latin Americans 
       Asians 
       Others  
 
81.4 (206) 
0.8 (2) 
4.0 (10) 
1.2 (3) 
12.6 (32) 
 
56.1 (37) 
21.2 (14) 
1.5 (1) 
1.5 (1) 
0.2 (13) 
 
 
 
<.0001 
 
   Risk factor, % (n)  
       Heterosexual sex 
       Men having sex with men 
       Intravenous drug use 
       Other  
 
58.9 (149) 
29.3 (74) 
9.1 (23) 
2.8 (7) 
 
78.8 (52) 
12.1 (8) 
6.1 (4) 
3.3 (2) 
 
 
.013 
   Gender, % (n) 
       Males  
 
73.9 (184) 
 
60.6 (40) 
.046 
   Age (yr), median (IQR*)  41 (34-47) 35 (32-41) .001 
   HIV-1 RNA (Log cp/mL), median (IQR)  5.1 (4.7-5.5) 4.9 (4.2-5.4) .049 
   CD4 count (cells/mL), median (IQR)  198 (64-323) 182 (64-286) n.s. 
   Total patients, % (n)   79.3 (253) 20.7 (66)  
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Among these individuals 54.5% (n=153), 36.3% (n=102) and 9.2% 
(n=26) carried 0, 1-3 and >3 mutations in protease region as detected 
before starting or changing therapy. An antiretroviral regimen 
containing an NNRTI was started in 225 individuals, 7 of whom had a 
transmitted NNRTI mutation.  
 
Table 5. Prevalence of drug resistance before the beginning of a new 
HAART regimen in naïve and experienced subjects, according to 
subtype. 
 
 
All 
patients 
NAÏVE PATIENTS EXPERIENCED 
PATIENTS 
B non-B B Non- B 
Any resistance % (n)  
57.0 
(631) 
9.9 (25) 6.1 (4) 76.9 (561) 68.3 (41) 
NRTI resistance % (n)  
52.0 
(576) 
7.5 (19) 6.1 (4) 70.6 (515) 63.3 (38) 
NNRTI resistance% (n)  
28.7 
(318) 
3. 2 (8) 4.6 (3) 39.4 (287) 33.3 (20) 
PI resistance % (n)  
24.3 
(269) 
2.8 (7) 0 33.3 (243) 31.7 (19) 
Previous drug regimens,  
median (IQR)  
3 (0-7) - - 5 (3-8) 3 (1-7) 
Total patients, % (n)   
100 
(1,108) 
79.3 
(253) 
20.7 (66) 92.4 (729) 7.6 (60) 
 
 
Virological response to HAART 
 
In the whole study population the proportion of subjects achieving 
virological suppression on HAART at median week 12 was higher in 
individuals carrying non-B (62/126, 49.2%) rather than B variants 
(387/982, 39.4%, p=.035). Subgroup analysis showed no difference 
either among drug-naïve (34/66, 51.5% vs. 105/253, 41.5%) or 
pretreated individuals (28/60, 46.7% vs. 282/729, 38.7%). No 
difference in virological response was detected in the proportion of 
  
individuals starting a PI
subtype (45/96, 46.9% vs. 309/787, 39.7%, in patients with non
and B clades). A trend to a better virological response was observed in 
subjects undergoing NNRTI
subtypes (17/30, 56.7% vs. 78/195, 40%; p=.085
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Prevalence of virological response to HAART at the median 
week 12 among naïve and experienced subjects.
 
 
No difference was detected when comparing the viral load reduction 
between baseline and the median week 12 between 
non-B and B subtypes when stratified between drug
experienced subjects (2.24 vs. 1.82 and 2.83 vs. 2.98 Log copies/ml, 
-containing HAART regimen accordi
-based HAART carrying non-B rather than B 
).  
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respectively). 
We investigated the response to treatment as the proportion of 
subjects achieving virological response at median week 24 in a subset 
of 777 individuals (70.1%) with an available follow up at this time-
point. No difference was found when grouped together (56/89, 62.9% 
vs. 379/688, 55.1%), in naïve (35/49, 71.6% vs. 145/189, 76.7%) or 
in experienced patients (21/.40, 52.5% vs. 234/499, 46.9%). 
 
 
Predictors of response to treatment 
 
With the whole case file, predictors of a higher probability of virological 
suppression at week 12 in the univariate analysis included subtype 
(OR, for non-B variants: 1.49; 95% CI: 1.02-2.16; p=.035), viral load 
at baseline (OR per 1 Log higher: 0.55; 95% CI: 0.47-0.65; p<.0001), 
time of virological follow-up (OR per 1 week higher: 1.01; 95% CI: 1-
1.11; p=.051), number of previous regimens (OR per 1 regimen 
higher: 0.95; 95% CI: 0.92-0.97; p<.0001) and calendar year (OR per 
1 year later: 1.21; 95% CI: 1.14-1.28; p<.0001). By contrast, 
ethnicity, mode of transmission, gender and age, as well as NNRTI or 
PI-containing regimens, did not influence the outcome of therapy. 
Predictors of viral load below 50 copies/ml in the multivariate model 
were viral load at baseline (OR per 1 Log higher: 0.41; 95% CI: 0.34-
0.50; p<.0001), number of previous regimens (OR per 1 regimen 
higher: 0.92; 95% CI: 0.89-0.95; p<.0001) and calendar year (OR per 
1 year higher: 1.27; 95% CI: 1.19-1.37; p<.0001).  
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Table 6. Logistic regression analysis investigating possible predictors 
of undetectable levels of HIV1 RNA at median week 12 in naïve 
individuals.  
a Other: Africans, Latin Americans, Asians or not available;   
b Other: professional risk, transfusions, vertical transmission. 
 
 
 
 
 
  
 Univariate Multivariate 
Covariate OR 95%CI p OR 95%CI p 
Subtype 
B 
Non-B 
 
- 
1.498 
 
- 
0.870-2.579 
 
- 
0. 145 
 
- 
0.963 
 
- 
0.467-1.986 
 
- 
0.919 
Ethnicity 
Europeans 
Other
a
 
 
- 
2.264 
 
- 
1.052-4.873 
 
- 
0.037 
 
- 
2.145 
 
- 
0.797-5.773 
 
- 
0.131 
 
Risk category 
HE 
HO 
IDU 
Other
b
 
 
 
- 
0.567 
0.875 
0.547 
 
 
- 
0.333-0.967 
0.390-1.963 
0.133-2.247 
 
 
- 
0.037 
0.746 
0.403 
 
 
- 
1.136 
1.715 
0.130 
 
 
- 
0.549-2.353 
0.662-4.441 
0.014-1.241 
 
 
- 
0.731 
0.266 
0.076 
 
Gender 
Male 
Female 
 
 
- 
2.085 
 
 
- 
1.272-3.418 
 
 
- 
0.004 
 
 
- 
2.201 
 
 
- 
1.141-4.243 
 
 
- 
0.018 
 
Age 
per 10  years older 
 
 
1.067 
 
 
0.857-1.328 
 
 
0.561 
 
 
1.331 
 
 
0.988-1.793 
 
 
0.060 
 
Time of viral load follow-up 
per 1 week higher 
 
1.099 
 
0.994-1.216 
 
0.065 
 
1.174 
 
1.032-1.336 
 
0.015 
 
Baseline viral load  
per 1 log higher 
 
0.369 
 
0.257-0.530 
 
<.0001 
 
0.335 
 
0.216-0.512 
 
<.0001 
 
Starting HAART 
PI  
NNRTI 
 
 
- 
0.735 
 
 
- 
0.453-1.192 
 
 
- 
0.212 
 
 
- 
0.590 
 
 
- 
0.323-1.077 
 
 
- 
0.086 
 
Number of previous regimens 
per 1 regimen higher 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Calendar year 
per 1 year higher 
1.123 1.024-1.231 0.014 1.190 1.066 -1.342 0.002 
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Table 6. Logistic regression analysis investigating possible predictors 
of undetectable levels of HIV1 RNA at median week 12 in drug-
experienced individuals.  
a Other: Africans, Latin Americans, Asians or not available;   
b Other: professional risk, transfusions, vertical transmission. 
 
 
 
 
  
 Univariate Multivariate 
Covariate OR 95%CI p OR 95%CI p 
Subtype 
B 
Non-B 
 
- 
1.387 
 
- 
0.817-2.353 
 
- 
0.225 
 
- 
1.283 
 
- 
0.639-2.576 
 
- 
0.483 
Ethnicity 
Europeans 
Other
a
 
 
- 
0.728 
 
- 
0.356-1.489 
 
- 
0.384 
 
- 
0.585 
 
- 
0.254-1.348 
 
- 
0.208 
 
Risk category 
HE 
HO 
IDU 
Other
b
 
 
 
- 
0.882 
0.977 
0.602 
 
 
- 
0.590-1.319 
0.707-1.351 
0.269-1.347 
 
 
- 
0.541 
0.889 
0.216 
 
 
- 
1.247 
1.060 
0.425 
 
 
- 
0.727-2.140 
0.698-1.608 
0.133-1.359 
 
 
- 
0.423 
0.785 
0.149 
 
Gender 
Male 
Female 
 
 
- 
1.041 
 
 
- 
0.767-1.414 
 
 
- 
0.794 
 
 
- 
0.996 
 
 
- 
0.654-1.517 
 
 
- 
0.985 
 
Age 
per 10  years older 
 
 
1.138 
 
 
0.950-1.364 
 
 
0.164 
 
 
1.091 
 
 
0.870-1.368 
 
 
0.452 
 
Time of viral load follow-up 
per 1 week higher 
 
1.038 
 
0.975-1.106 
 
0.245 
 
1.026 
 
0.950-1.107 
 
0.516 
 
Baseline viral load  
per 1 log higher 
 
0.519 
 
0.426-0.633 
 
<.0001 
 
0.4230 
 
0.338-0.548 
 
<.0001 
 
Starting HAART 
PI  
NNRTI 
 
 
- 
1.100 
 
 
- 
0.747-1.620 
 
 
- 
0.628 
 
 
- 
1.260 
 
 
- 
0.807-1.968 
 
 
- 
0.309 
 
Number of previous regimens 
per 1 regimen higher 
 
0.942 
 
0.910-0.975 
 
0.0008 
 
0.922 
 
0.884-0.963 
 
0.0002 
Calendar year 
per 1 year higher 
1.255 1.170-1.345 <.0001 1.352 1.233 -1.482 <.0001 
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HAART effect in paired pol genotype 
 
We evaluated whether mutations associated to resistance differently 
influence the proportions of subtype B and non-B infected patients 
achieving an undetectable viral load at week 12 when beginning a PI- 
or an NNRTI-containing HAART. The procedure used to code HIV-1 
genotype generated 35 and 12 vectors for PI- and NNRTI-treated 
patients, respectively. Table 3 shows the patterns of mutations 
identified and the proportions of patients with B or non-B subtypes 
who achieved an undetectable viral load at week 12.  
Among patients on PI-based regimens, the rate of virological response 
was not different between subtype B and non-B virus either in the 
absence of drug resistance mutations (group 1) or in the presence of 
any of the most common mutational patterns found. Patients harboring 
a wild type HIV-1 genotype were the only group allowing comparisons 
between subtype B and specific non-B subtypes. No significant 
difference was observed in this group when subtype F1 (n=13) and C 
(n=9) were compared to subtype B (n=324) (response rates of 23.1% 
and 44.4% vs. 36.7%,respectively). By contrast, a better response in 
patients carrying CRF02_AG (n=12) compared to those with HIV-1 B 
clade (75.0% vs. 36.7%, p=.012) was observed.  
Among patients on NNRTI-based regimens, no difference in the 
response rate was found between subjects harboring non-B or B 
subtypes when mutations were absent at baseline. Finally, HIV-1 RNA 
reduction at the median week 12 and the proportions of response to 
treatment at median week 24 in patients matched for specific mutation 
patterns and specific genotype did not  significantly differ between 
non-B and B clade. 
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Table 7. Resistance patterns and response to treatment in patients 
carrying non-B and B subtypes. 
a
0: no mutations; 1: 1-3 mutations; 2: >3 mutations 
b
0: no mutations; 1: any mutations 
 
 
Vectors  Mutation pattern  
Subtype  Response to HAART  
TAM  65R  74V  151M  184V  PI 
a
  
Non-B  
% (num.)  
B  
% (num.)  
Non-B  
% (num.)  
B  
% (num.)  
1  0  0  0  0  0  0  15.4 (59)  84.6 (324)  40.7 (24)  36.7 (119)  
2  0  0  0  0  1  0  13.2 (9)  86.8 (59)  44.4 (4)  57.6 (34)  
3  1  0  0  0  0  0  4.4 (4)  95.6 (86)  75.0 (3)  41.9 (36)  
4  1  0  0  0  1  0  5.2 (4)  94.8 (73)  75.0 (3)  42.5 (31)  
5  1  0  0  0  0  1  10.9 (7)  89.1 (57)  28.6 (2)  26.3 (15)  
6  1  0  0  0  1  1  4.1 (3)  95.9 (71)  33.3 (1)  42.3 (30)  
7  0  0  0  0  0  1  12.5 (2)  87.5 (14)  100 (2)  42.9 (6)  
8  0  0  0  0  1  1  7.7 (1)  92.3 (12)  0 (0)  33.3 (4)  
9  0  0  1  0  0  0  50 (2)  50 (2)  100 (2)  50 (1)  
10  0  1  0  0  0  0  20 (1)  80 (4)  100 (1)  100 (4)  
11  1  0  1  0  1  0  10 (1)  90 (9)  100 (1)  66.7 (6)  
12  1  0  1  0  1  1  20 (1)  80 (4)  100 (1)  50 (2)  
13  1  0  1  0  1  2  20 (1)  80 (4)  100 (1)  100 (4)  
 
TAM  65R  74V  151M  184V  NNRTI  
        
14  0  0  0  0  0  0  16.3 (24)  83.7 (123)  62.5 (15)  50.4 (62)  
15  0  0  0  0  0  1  50 (1)  50 (1)  100 (1)  100 (1)  
16  0  0  0  0  1  0  12.5 (2)  87.5 (14)  0 (0)  57.1 (8)  
17  1  0  0  0  1  0  6.9 (2)  93.1 (27)  50 (1)  18.5 (5)  
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Overall access to antiretrovirals through global or local treatment 
programs is increasing in low-income areas where non-B HIV-1 strains 
are highly prevalent. Although the circulation of non-B subtypes has 
recently increased in most European countries, response to treatment 
in Western countries has been mainly analyzed with subtype B viruses 
and in some cases compared with that of non-B subtypes considered 
as a single cumulative group [19, 20]. This approach may mask 
differences among specific subtypes in disease progression and drug 
susceptibility [25, 41]. Indeed, medium-term outcome of large studies 
in low-income countries demonstrated good virological and 
immunological responses to therapy, but few studies have addressed 
treatment response with specific subtypes [42-44]. Some reports 
indicated subtype-independent effects of HAART [45] while others 
suggested that D subtype, compared to C and A clades, negatively 
impacts on disease progression and response to treatment [47-49]. 
 
We studied a large population of either naïve or drug experienced HIV-
1 patients who started an antiretroviral therapy guided by a baseline 
genotype over the last 13 years in Italy. We recently reported evidence 
of onward transmission of non-B variants through migration and 
travels among Caucasian living in Italy [36]. Other Italian studies 
indicated that such viral variants are spreading to heterosexuals and 
male homosexuals, thus non-B subtypes are no longer restricted to 
African ethnicity and heterosexuality [37, 38]. 
 
A high heterogeneity of group M HIV-1 clades was detected in our 
Discussion 
 33
study population. Of note, F1 subtype and CRF02_AG accounted for 
similar proportions (about 20%) of non-B strains. In previous studies 
the very low frequency of F1 subtypes did not allow to address their 
response to HAART therapy [27, 45, 49]. Overall, the prevalence of 
any and class-specific drug resistance mutations was lower in non-B 
compared to B clade in our case-file. However, no difference in TDR 
was detected in naive patients carrying either non-B or B subtype. This 
finding indicates that primary resistance is no longer restricted to 
patients of Caucasian ethnicity mainly infected with subtype B. An 
explanation of these data may be the lower frequency (about 8%) of 
non-B clades in drug experienced patients compared to that found in 
naive individuals (about 21%). The former subjects may have acquired 
HIV-1 infection at an earlier time point when the circulation of non-B 
variants, including transmission of resistant strains, was lower than 
that found in the last years [39]. 
 
As expected, the relative proportion of treated individuals was lower 
among those with a non-B clade, who received a median lower number 
of regimens compared to patients carrying a B subtype. By studying 
the overall population we observed a better response to HAART of non-
B variants regardless of the class of drugs used together with an NRTI 
backbone. However, this difference in the virological outcome was still 
present but not significant when comparing patients who received an 
NNRTI- or PI containing regimen either in naïve or previously treated 
individuals, probably due to a size effect. A slightly better response 
was observed in patients with non-B clades on NNRTI-containing 
regimens. This finding is not in agreement with the results of the ACTG 
5095 trial that indicated a higher risk of virological failure of efavirenz 
therapy in black patients with respect to white Americans [50]. 
Nonetheless, the multivariate analysis supported our finding 
demonstrating that the ethnicity does not influence the short-term 
response to HAART. 
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Moreover, a limited proportion of subjects achieved viral suppression 
at week 12. This result may be partly explained by i) the high 
proportion (more than 25%) of patients with HIV-1 viral load above 
106 copies/ml and ii) the relatively short follow-up which was 
deliberately chosen to focus on the impact of genotype on virological 
response. In any case, no worse response of non-B clades was 
detected even analyzing the difference in HIV-RNA reduction at week 
12 or the proportion of individuals reaching viral load suppression at 
week 24. 
Due to its retrospective nature, our study has several limitations, 
particularly the lack of any information about adherence to treatment. 
It has been proposed that the maintenance of long-term adherence 
may be influenced by effective engagement of health care facilities 
[50]. Although we could not check for adherence in our database, the 
free access to Italian medical services and the availability of therapy 
for legal or illegal immigrants could have favoured their compliance to 
therapy regardless of their ethnicity. Moreover, an interaction between 
race and adherence has been only reported for an NNRTI, efavirenz, 
due to a genetic polymorphism of the subfamily of cytochrome P450 
(CYP2B26) in blacks that leads to a decreased metabolism of this drug, 
relevant side effects and low adherence [50]. A number of factors 
possibly affecting adherence, such as ethnicity, age, gender and risk 
factors, were considered as possible confounders in our regression 
model. None of these covariates significantly resulted to impact the 
virological outcome of patients stratified according to treatment status 
and subtypes in the multivariate analysis. In addition, although CD4 
cell count at baseline was higher in subjects carrying a subtype B, this 
parameter was not associated with different virological outcome 
neither in univariate nor  multivariate analysis. 
 
Furthermore, even though a genotype guided choice of regimens 
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warrants for avoiding suboptimal therapy in naïve patients, this may 
not be fully applied to experienced patients, particularly those with 
multiple failures. Indeed, we observed that the number of previous 
regimens interacts with treatment response, however, this factor was 
considered as a confounder in the multivariate analysis. The treatment 
cases included in our study span 14 years. During this period several 
drugs have been replaced by more potent compounds and, as 
expected, the more recent calendar year of treatment was a predictor 
of virological success.  
 
Our findings indicate that the efficacy of NNRTI- or PI-containing 
HAART is similar with B and non-B subtypes matched for major 
resistance mutations. This suggests that HIV-1 pol minor mutations 
and polymorphisms do not significantly impact response to HAART with 
HIV-1 subtype B vs. non-B. Based upon discrepant results of different 
interpretation algorithms, it has been suggested that polymorphisms 
could impact the outcome of patients with non-B variants [51, 52]. 
However, the potential influence of mutations associated to minor 
resistance has been studied in detail in a paper analyzing amino acid 
protease and RT changes of about two hundred non-B clinical isolates 
of naïve and treated HIV-1 patients. By using the Virtual PhenotypeTM 
tool and linear regression analysis it has been observed that individual 
unreported changes not belonging to known resistance mutations are 
not predictors of resistance of non-B variants [27].  
 
By comparing sequences with identical patterns of major resistance 
mutations, we could compare virological outcome only in a limited 
number of individual HIV-1 clades (F1, CRF02_AG and C). The data 
suggest that response to HAART for these HIV-1 variants is 
comparable to that detected for B subtype. These data support 
previous results and extend them to the F1 subtype [45]. However, 
achievement of viral suppression was detected in an higher proportion 
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of patients infected with the CRF02_AG clade, compared to B subtype, 
starting a PI-containing regimen with a wild type virus. Even though 
the number of patients carrying CRF02_AG is limited, a possible 
influence of clade-specific polymorphisms on the therapeutic outcome 
cannot be excluded, thus requiring further investigations. 
 
Our study provides early data showing similar responses of non-B and 
B clades even when paired for genotype, even though extended follow-
up data are required to provide conclusive results. While it cannot be 
ruled out that specific combinations of mutations and specific 
polymorphisms exert different effects on drug susceptibility with a 
particular clade, larger datasets, most likely derived from international 
cohorts, are required to address this possibility. 
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